Loading
The first prospective trial in small bowel adenocarcinoma found that the colorectal cancer regimen CAPOX shrank tumours in half of patients, and it became the backbone of treatment and of the adjuvant BALLAD trial.
Single-centre phase 2 study of 30 patients with untreated advanced adenocarcinoma of the small bowel or ampulla of Vater treated with capecitabine and oxaliplatin (CAPOX) every three weeks.
The objective response rate was 50 percent, median time to progression 11.3 months and median overall survival 20.4 months, with results in the small bowel subgroup at least as good. The regimen was adopted as a standard for advanced disease and the basis for adjuvant trials.
Fluoropyrimidine plus oxaliplatin is the first-line chemotherapy for advanced small bowel adenocarcinoma and the regimen tested after surgery in BALLAD.
Shares CAPOX (capecitabine, oxaliplatin), Journal of Clinical Oncology.
Shares Localised small bowel adenocarcinoma (stage I to III, resected), Advanced and metastatic small bowel adenocarcinoma, CAPOX (capecitabine, oxaliplatin).
Shares CAPOX (capecitabine, oxaliplatin), Journal of Clinical Oncology.